Nyrada
Menu
NYR:
Market Cap*:
Price Delay ~20min
Home
About Us
Company Overview
Board of Directors
Management
Scientific Advisory Board
Corporate Governance
Our Science
Lead Drug Development
Brain Injury Program
Cholesterol Lowering Program
Technical Glossary
Drug Development Pathway
Investors
Investor Welcome
Company Fact Sheet
ASX Announcements
Brain Injury Program
Cholesterol-Lowering Program
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Key Dates
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Extraordinary General Meeting
Past Shareholder Meetings
News & Insights
Presentations & Interviews
Media
Newsletters
Publications
Contact Us
Contact Us
Working at Nyrada
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
>
Brain Injury Program
Investor Welcome
Company Fact Sheet
ASX Announcements
Brain Injury Program
Cholesterol-Lowering Program
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Key Dates
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Extraordinary General Meeting
Past Shareholder Meetings
Brain Injury Program
Filter by Year:
2024
2023
2022
2021
2020
9-Sep-2024
Brain Injury Program GLP Studies Further Update 4
20-Aug-2024
Brain Injury Program GLP Studies Further Update No 3
6-Aug-2024
Brain Injury Program GLP Studies Further Update
16-Jul-2024
GLP Studies Update
26-Jun-2024
NYR Signs Strategic Partnership with US Brain Injury Company
30-Apr-2024
Nyrada Commences Walter Reed Traumatic Brain Injury Study
28-Mar-2024
Nyrada Commences Key Brain Injury Program Preclinical Study
28-Feb-2024
Significant Neuroprotection in NYR Preclinical Brain Injury
1
